Spots Global Cancer Trial Database for A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
Official Title: Phase 2 Open-Label Study of Volociximab (M200) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer Not Previously Treated With Chemotherapy
Study ID: NCT00401570
Conditions
Study Description
Brief Summary: This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 70538, Pittsburgh, Pennsylvania, United States
Site Reference ID/Investigator# 70537, Nashville, Tennessee, United States
Site Reference ID/Investigator# 70534, Glasgow, , United Kingdom
Site Reference ID/Investigator# 70533, Leeds, , United Kingdom
Site Reference ID/Investigator# 70536, Manchester, , United Kingdom
Site Reference ID/Investigator# 70535, Northwood, , United Kingdom
Contact Details
Name: Mihail Obrocea, MD
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
